|
Age ≥ 50 years
|
0.94
|
(0.63, 1.40)
|
0.760
|
|
ECOG performance status
| | | |
|
2 – 3 versus 0 – 1
|
1.81
|
(1.21, 2.72)
|
0.004
|
|
Hydroxyproline/Creatinine ratio (centered)
|
1.00
|
(0.97, 1.04)
|
0.921
|
|
Bone-specific alkaline phosphatase, U/L
|
1.01
|
(1.00, 1.01)
|
0.204
|
|
Estrogen-receptor status versus negative
| | | |
|
Positive
|
0.56
|
(0.34, 0.92)
|
0.023
|
|
Unknown
|
0.89
|
(0.58, 1.36)
|
0.580
|
|
Progesterone-receptor status versus negative
| | | |
|
Positive
|
0.62
|
(0.38, 1.01)
|
0.053
|
|
Unknown
|
0.78
|
(0.52, 1.16)
|
0.214
|
|
Sites of metastasis (yes versus no)
| | | |
|
Bone as only metastatic site
|
0.84
|
(0.57, 1.24)
|
0.392
|
|
Lung
|
1.32
|
(0.77, 2.29)
|
0.317
|
|
Liver
|
1.26
|
(0.75, 2.13)
|
0.379
|
|
Time from diagnosis of bone metastases to study entry, years
|
1.00
|
(0.95, 1.04)
|
0.912
|
|
Time from cancer diagnosis to study entry, years
|
1.00
|
(0.96, 1.04)
|
0.947
|
|
Lesion characteristics and numbers
| | | |
|
≥ 3 osteolytic versus < 3 osteolytic
|
1.92
|
(1.29, 2.84)
|
0.001
|
|
1 – 2 osteoblastic versus no osteoblastic
|
1.28
|
(0.82, 2.02)
|
0.282
|
|
≥ 3 osteoblastic versus no osteoblastic
|
0.39
|
(0.32, 0.50)
|
< 0.001
|
|
1 – 2 mixed versus no mixed
|
1.16
|
(0.64, 2.09)
|
0.624
|
|
≥ 3 mixed versus no mixed
|
1.26
|
(0.77, 2.06)
|
0.352
|
|
Prior fracture (yes versus no)
|
1.78
|
(1.12, 2.81)
|
0.014
|
|
Pain scores (centered)
|
1.29
|
(1.19, 1.40)
|
< 0.001
|
|
Prior chemotherapy (yes versus no)
|
0.89
|
(0.32, 2.48)
|
0.816
|
|
≥ 2 prior hormonal therapies (yes versus no)
|
1.11
|
(0.75, 1.63)
|
0.605
|
|
Prior radiotherapy (yes versus no)
|
2.02
|
(1.35, 3.02)
|
< 0.001
|
